/ EN

BCIwiki — Brain-computer interface news, research and industry database

Latest

September 2026

Shandong Health Commission Leads 16-Agency Push on BCI Clinical Validation

Shandong's health commission and 15 other agencies issued a BCI clinical translation plan on July 7, 2026, following a 2025 industry plan led by the provincial science department. The 14-measure plan sets up a clinical research alliance and a provincial clinical database, cuts review time for Class II devices to 90 working days, and targets more than 30 multicenter validation projects and a RMB 2 billion industry by 2028.
Why it matters Shandong is the only province to split industry and clinical policy into separate documents led by different agencies, targeting the clinical evidence gap that holds back medical BCIs, yet it has still not published BCI service prices.

Jiangxi Sets 10-Day Clock for Mutual Recognition of BCI Ethics Reviews

Jiangxi issued BCI support measures on November 26, 2025 that set no numeric targets but called for mutual recognition of clinical research ethics reviews, and its health commission followed on May 26, 2026 with guidance requiring participating sites to finish recognition reviews within 10 working days. Invasive projects for neurological or psychiatric treatment also need provincial expert review within 20 working days.
Why it matters Repeated ethics reviews at every site are one of the slowest steps in multicenter BCI trials, and Jiangxi is the only province so far to follow a policy pledge with binding deadlines within six months.

Jiangsu Opens BCI Trials to Nuclear, Mining and Power Industries

Jiangsu's industry department and eight other agencies issued a BCI action plan in March 2026 that invites companies in hazardous chemicals, nuclear power, mining and electric power to pilot the technology first. Nearly all its numeric targets, including at least 20 registered medical products, fall in 2030, and a widely cited RMB 6,600 implant price appears only in a 2025 draft, not in the province's final pricing notice.
Why it matters Jiangsu is the only province to name hazardous industries as BCI testbeds, a route that avoids device registration and insurance, but its 2030-only targets and draft-stage price are often misread as more aggressive than they are.

Tianjin Stakes BCI Product Targets on Non-Invasive Devices

Tianjin's municipal government issued a 2026-2030 BCI action plan on May 26, 2026 that limits every numeric product target to non-invasive devices, aiming for more than ten in large-scale clinical use by 2030, while invasive products get a single unquantified approval goal. The plan also targets an industry fund cluster of more than RMB 10 billion by 2030.
Why it matters Rather than compete with Beijing and Shanghai on neurosurgical capacity, Tianjin concentrates on non-invasive products, standards and funds, and its bid for a national BCI technology innovation center is the plan's biggest single variable.

Guangdong Plans 200 BCI Wards and Splits Roles Between Shenzhen and Guangzhou

Guangdong's provincial Party science and technology committee office issued a 2026-2030 BCI plan on June 5, 2026 that calls for 200 BCI hospital wards serving more than 500,000 patients cumulatively by 2030. The plan assigns invasive devices and signal decoding to Shenzhen and non-invasive systems to Guangzhou, and follows provincial BCI prices set nine months earlier, with implantation capped at RMB 6,600.
Why it matters Guangdong measures clinical capacity itself and gives its two rival cities separate technology lanes, but with no insurance coverage yet, the plan does not say why hospitals would invest in 200 wards.

Zhejiang, First to Reimburse BCI Fees, Cuts Device Review to 40 Days

Zhejiang became the first Chinese province to reimburse a BCI service when it covered non-invasive fitting fees under Category B insurance from September 1, 2025, limited to smart bionic prosthesis fittings. Its 18 industry-academia-research measures, dated July 16, 2026, cut review of qualifying Class II BCI devices to 40 working days and offer research hospitals up to RMB 8 million per project.
Why it matters Zhejiang opened reimbursement with the cheapest, narrowest BCI item while invasive surgery stays self-paid, and its industry-first measures target the incentive problem that keeps public hospitals out of preclinical research.

Fujian Plans Cross-Strait BCI Lab in 2026-2030 Action Plan

Fujian's science department and five other agencies issued a 2026-2030 BCI action plan on August 9, 2026, making the province the 11th in China with a dedicated BCI policy. It plans a cross-strait joint laboratory with Taiwanese research institutions and companies by 2027 and targets 30 innovative companies and a RMB 3 billion industry by 2030.
Why it matters Fujian is the only province to build Taiwan cooperation into its BCI policy, though its targets are modest, focused on non-invasive EEG, and still await details on who leads the joint lab and how much funding it gets.

Hubei, Without a BCI Policy Plan, Was First to Price BCI Services

Hubei became the first Chinese province to publish BCI medical service prices on March 31, 2025, capping invasive implantation at RMB 6,552, and Wuhan hosted China's first BCI operation charged at the government guidance price in November 2025. The province has no dedicated BCI policy document, and its prices carry no insurance payment category.
Why it matters Hubei shows that prices and park-level incentives can move ahead without a provincial plan, but without provincial coordination its activity stays concentrated in Wuhan and reimbursement lags Zhejiang and Beijing.

Without BCI Industry Plans, Hainan, Qinghai and Xinjiang Price BCI Services First

As of September 14, 2026, 11 of China's 31 provincial-level regions had issued dedicated BCI policy documents, but Hainan, Qinghai and Xinjiang had published BCI medical service prices without any industry plan. Hubei, Hunan, Chongqing and Henan have BCI initiatives but no dedicated documents, and 16 other regions show neither.
Why it matters Pricing needs only a cost calculation by the insurance agency, not an industrial base, so it is spreading faster than industry plans, and less-equipped provinces are likely to enter BCI through payment first.

Tsinghua Team Launches TrustBCI to Share BCI Data Without Moving It

Training accurate BCI models depends on large, diverse EEG datasets, but that data is usually locked inside individual hospitals and labs, stored in inconsistent formats and restricted by privacy rules, which makes it hard to share. TrustBCI brings three functions into one platform: turning raw BCI datasets into assets that can be exchanged, using incentives to keep institutions contributing data, and letting users run computations without access to the raw records. The platform demonstrates two workflows, controllable data synthesis, which generates new datasets, and privacy-preserving query, which returns only query results. That suggests BCI models could be trained jointly across institutions without first pooling the data in one place.
Why it matters The BCI field's data shortage stems less from a lack of collection than from the fact that recorded data cannot leave the institution that holds it. This platform combines data assetization, contribution incentives and privacy-preserving computation in a single process and comes with a working web prototype, showing that cross-institution sharing is workable in engineering terms. It tackles data circulation, not decoding accuracy, and real-world uptake will depend on how many institutions are willing to connect their data.

© 2026 BCIwiki.com Digest Topics Tips Subscribe Revisions About